Clinical Trial Detail

NCT ID NCT01431209
Title Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Nebraska|Incyte Corporation
Indications

peripheral T-cell lymphoma

diffuse large B-cell lymphoma

Therapies

Ruxolitinib

Age Groups: adult

No variant requirements are available.